← Back to Search
Standard Chemotherapy Options And Clinical Trials Of Novel Agents For Mesothelioma
Published 2017 · Medicine
Download PDFAnalyze on Scholarcy
Despite recent dramatic advances in many solid tumors, malignant mesothelioma remains challenging to treat. Historically, because of the modest number of cases globally and the substantial geographic distribution of patients, large randomized clinical trials were difficult and lengthy to complete, and thus, interest from pharmaceutical companies was limited. Additionally, financial support from various funding agencies is limited for this orphan disease. Consequently, most studies of systemic therapy for mesothelioma were small phase II trials. Despite these limitations, several standards of care were established. This chapter reviews standard cytotoxic chemotherapy treatment for malignant mesothelioma and discusses many novel agents recently and currently under investigation in clinical trials. The roles of surgery, radiation treatment, and combined modality therapy are covered in accompanying chapters. Furthermore, the ongoing development of immunotherapeutic agents is discussed in an accompanying chapter by Hassan and colleagues.
This paper references
An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma
G. Falkson (2004)
Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230
C. Blackwell (2016)
Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation.
J. Neuzil (2004)
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
S. Knutson (2012)
Pemetrexed Alone or in Combination with Cisplatin in Previously Treated Malignant Pleural Mesothelioma: Outcomes from a Phase IIIB Expanded Access Program
P. Jänne (2006)
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
A new standard for malignant pleural mesothelioma
M. Zauderer (2016)
Gemcitabine and vinorelbine in pemetrexed‐pretreated patients with malignant pleural mesothelioma
P. Zucali (2008)
Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1
Matthew Locke (2016)
WT1 MUTATION IN MALIGNANT MESOTHELIOMA AND WT1 IMMUNOREACTIVITY IN RELATION TO p53 AND GROWTH FACTOR RECEPTOR EXPRESSION, CELL‐TYPE TRANSITION, AND PROGNOSIS
S. Kumar-Singh (1997)
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
J. Bissler (2013)
Phase II trial of vindesine in malignant pleural mesothelioma.
C. Boutin (1987)
BAP1/ASXL1 recruitment and activation for H2A deubiquitination
Danny D. Sahtoe (2016)
Efficiency of recombinant human TNF in human cancer therapy.
F. Lejeune (2006)
Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program
A. Santoro (2008)
Malignant mesothelioma. The eastern cooperative oncology group (ECOG) experience
H. Lerner (1983)
Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck
F. Göke (2013)
Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions
A. Dar (2008)
New Strategies in Pleural Mesothelioma: BAP1 and NF2 as Novel Targets for Therapeutic Development and Risk Assessment
M. Ladanyi (2012)
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.
Güllü T Görgün (2010)
Arginine and glycine stimulate creatine synthesis in creatine transporter 1-deficient lymphoblasts.
V. Leuzzi (2008)
Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.
C. Manegold (2005)
Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma.
Mor-Li Hartman (2010)
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
P. Sonneveld (2013)
Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors
G. Shapiro (2011)
Tumor angiogenesis: therapeutic implications.
J. Folkman (1971)
Phase II Study of Intravenous Doxil® in Malignant Pleural Mesothelioma
Y. Oh (2004)
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.
H. Fine (2000)
Loss of aurora A/STK15/BTAK overexpression correlates with transition of in situ to invasive ductal carcinoma of the breast.
A. Hoque (2003)
Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.
D. Fennell (2005)
Mutant Fibroblast Growth Factor Receptor 3 Induces Intracellular Signaling and Cellular Transformation in a Cell Type- and Mutation-Specific Manner
E. di Martino (2009)
Regulatory role for the arginine-nitric oxide pathway in metabolism of energy substrates.
W. Jobgen (2006)
A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.
J. Dowell (2012)
Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.
A. Tsao (2014)
Loss of the Tumor Suppressor BAP1 Causes Myeloid Transformation
A. Dey (2012)
Malignant pleural mesothelioma: phase II pilot study of ifosfamide and mesna.
A. Alberts (1988)
Functional inactivation of NF2/merlin in human mesothelioma.
Claudio Thurneysen (2009)
Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma.
J. Steele (2001)
A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors
M. Gordon (2012)
Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.
V. Gregorc (2010)
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.
J. Stebbing (2009)
Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
S. Zhou (2014)
Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo
O. Abdelwahab (2013)
An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735
K. Hook (2012)
Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.
N. Katirtzoglou (2010)
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
Phase I study of recombinant human tumor necrosis factor
K. Kimura (2004)
A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma
A. Nowak (2012)
Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma.
Makio Moriya (2014)
Aurora-A: the maker and breaker of spindle poles
A. Barr (2007)
Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).
S. Kalmadi (2008)
High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies.
H. Avet‐Loiseau (1998)
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
H. Kindler (2012)
Single-Agent Pemetrexed for Chemonaïve and Pretreated Patients with Malignant Pleural Mesothelioma: Results of an International Expanded Access Program
Paul Taylor (2008)
VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours
Y. Ohta (1999)
G2 checkpoint abrogators as anticancer drugs.
T. Kawabe (2004)
P2.01: LUME-MeSO: Phase II/III Study of Nintedanib + Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Track: SCLC, Mesothelioma, Thymoma.
G. Scagliotti (2016)
A phase I trial of recombinant tumor necrosis factor (rTNF) administered by continuous intravenous infusion in patients with disseminated malignancy
J. Schwartz (1989)
Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies.
F. Izzo (2004)
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
A. Nowak (2002)
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma
A. Favaretto (2003)
Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma
E. Mbidde (2004)
Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway.
L. Liu (2004)
Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma
R. Orlowski (2016)
Removal of uracil by uracil DNA glycosylase limits pemetrexed cytotoxicity: overriding the limit with methoxyamine to inhibit base excision repair
A. Bulgar (2012)
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
W. Kelly (2005)
Phase II trial of topotecan for the treatment of mesothelioma.
A. Maksymiuk (1998)
Impaired angiogenesis in aminopeptidase N-null mice
R. Rangel (2007)
The Polycomb complex PRC2 and its mark in life
R. Margueron (2011)
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
T. Jahan (2012)
Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma
M. Duvic (2007)
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma
G. Gordon (2007)
Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial.
A. Mathy (2005)
Loss of the Tumor Suppressor Gene NF2, Encoding Merlin, Constitutively Activates Integrin-Dependent mTORC1 Signaling
M. López-Lago (2009)
Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM).
S. Cedrés (2012)
Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer
J. Syrios (2015)
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
S. Minucci (2006)
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
S. Knutson (2013)
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
M. T. McCabe (2012)
Phase II Trial of Pegylated-Liposomal Doxorubicin (Doxil™) in Mesothelioma
K. Skubitz (2002)
Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group
S. Laurie (2011)
EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity
J. E. Campbell (2015)
Phase II study of vinorelbine in patients with malignant pleural mesothelioma.
J. Steele (2000)
Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging.
M. Allen (2014)
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
R. Bueno (2016)
PI3K and cancer: lessons, challenges and opportunities
D. Fruman (2014)
Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.
Guangwu Guo (2015)
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1–Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial
P. Szlosarek (2017)
A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients
T-S Yang (2010)
A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma: A southwest oncology group study
B. Zidar (1992)
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
Aurora-A Kinase Maintains the Fidelity of Early and Late Mitotic Events in HeLa Cells*
T. Marumoto (2003)
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
M. Pavel (2011)
Nonamplified FGFR1 Is a Growth Driver in Malignant Pleural Mesothelioma
L. Marek (2014)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.
O. Abdelwahab (2012)
The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer
K. Vermeulen (2003)
Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker
Masashi Takawa (2011)
Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy
S. Papa (2013)
Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer
H. Carol (2011)
Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane
T. Okada (2005)
mTOR signaling and drug development in cancer
J. Dancey (2010)
Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells.
F. Curnis (2002)
A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
J. Van Meerbeeck (1999)
Fibroblast growth factor signaling in tumorigenesis.
R. Grose (2005)
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
S. Kumar (2012)
Temsirolimus Inhibits Malignant Pleural Mesothelioma Growth In Vitro and In Vivo: Synergism with Chemotherapy
M. A. Hoda (2011)
Role of protein kinase C β and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism
S. Loganathan (2011)
Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience
A. Bearz (2011)
Epigenetics in cancer: Targeting chromatin modifications
Leigh Ellis (2009)
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
G. Scagliotti (2003)
Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509
L. Garland (2011)
A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma.
J. Van Meerbeeck (2002)
Selective inhibition by methoxyamine of the apurinic/apyrimidinic endonuclease activity associated with pyrimidine dimer-DNA glycosylases from Micrococcus luteus and bacteriophage T4.
M. Liuzzi (1987)
The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992).
P. Baas (2003)
Retreatment with pemetrexed-based chemotherapy in malignant pleural mesothelioma (MPM): a second line treatment option.
A. Razak (2008)
Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors
S. Dolly (2016)
Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216.
C. Y. Peng (1997)
Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma.
P. Sørensen (1985)
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.
J. Yao (2010)
Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma
B. Davidson (2004)
Edatrexate (10‐ethyl‐deaza‐aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma
H. Kindler (1999)
Aurora Kinases: New Targets for Cancer Therapy
R. Carvajal (2006)
Identification of targetable FGFR gene fusions in diverse cancers.
Y. Wu (2013)
Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer
A. Dutt (2011)
Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma.
X. Cao (2001)
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
B. Castagneto (2008)
Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer.
D. Sutherlin (2011)
Fibroblast growth factor signalling: from development to cancer
N. Turner (2010)
Epigenetic therapy of cancer: past, present and future
C. Yoo (2006)
Malignant pleural mesothelioma: a phase II trial with docetaxel.
D. Vorobiof (2002)
Cell cycle control and cancer.
L. Hartwell (1994)
The Fgf families in humans, mice, and zebrafish: their evolutional processes and roles in development, metabolism, and disease.
N. Itoh (2007)
A Histone Deacetylase Inhibitor LBH589 Downregulates XIAP in Mesothelioma Cell Lines Which is Likely Responsible for Increased Apoptosis With TRAIL
J. Symanowski (2009)
Adding raltitrexed to cisplatin improves overall survival in people with malignant pleural mesothelioma.
C. Porta (2006)
Phase I trial of recombinant human tumour necrosis factor α in patients with advanced malignancy
H. Gamm (1991)
Phase I Clinical and Magnetic Resonance Imaging Study of the Vascular Agent NGR-hTNF in Patients with Advanced Cancers (European Organization for Research and Treatment of Cancer Study 16041)
H. V. van Laarhoven (2010)
Current concepts in malignant pleural mesothelioma
A. Kaufman (2008)
Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.
M. Zauderer (2014)
Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)
J. Maris (2010)
Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma.
C. Linder (1998)
SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model
Trung The Van (2012)
Deletion mapping of the short arm of chromosome 3 in human malignant mesothelioma
You Yong Lu (1994)
Phase II trial of mitomycin in malignant mesothelioma.
D. Bajorin (1987)
Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen
S. Jacobus (2016)
Caelyx in malignant mesothelioma: a phase II EORTC study.
P. Baas (2000)
The FGF family: biology, pathophysiology and therapy
A. Beenken (2009)
Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma
A. Mazumdar (2009)
Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study
G. Falchook (2014)
In vivo Loss of Expression of Argininosuccinate Synthetase in Malignant Pleural Mesothelioma Is a Biomarker for Susceptibility to Arginine Depletion
P. Szlosarek (2006)
Anticancer activities of histone deacetylase inhibitors
J. E. Bolden (2006)
Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Oncology Group.
C. Belani (2004)
A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days
P. Creaven (2004)
Histone Deacetylase Inhibitors in Malignant Pleural Mesothelioma: Preclinical Rationale and Clinical Trials
P. Paik (2010)
Proliferation, cell cycle and apoptosis in cancer
G. Evan (2001)
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
R. Motzer (2008)
Bortezomib Inhibits Nuclear Factor-κB–Dependent Survival and Has Potent In vivo Activity in Mesothelioma
A. Sartore-Bianchi (2007)
A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors.
A. Tolcher (2016)
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
L. Krug (2015)
Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.
H. Kindler (2001)
Phase II trial of carboplatin in the management of malignant mesothelioma.
D. Raghavan (1990)
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.
A. Palumbo (2010)
BAK and NOXA Are Critical Determinants of Mitochondrial Apoptosis Induced by Bortezomib in Mesothelioma
S. Busacca (2013)
A phase II study of vincristine in malignant mesothelioma — a negative report
G. Mårtensson (2004)
Transplacental carcinogenesis by stilbestrol.
J. Folkman (1971)
Nintedanib (BIBF 1120) blocks the tumor promoting signals of lung fibroblast soluble microenvironment.
G. Epstein Shochet (2016)
Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays
M. Manfredi (2011)
Loss of BAP1 function leads to EZH2-dependent transformation
Lindsay M. LaFave (2015)
Phase-I trial of intravenous continuous infusion of tumor necrosis factor in advanced metastatic carcinomas
B. Wiedenmann (2004)
BRCA1 is an essential mediator of vinorelbine‐induced apoptosis in mesothelioma
S. Busacca (2012)
Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group.
T. Sahmoud (1997)
High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234.
N. Vogelzang (1999)
High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631.
M. Kosty (2001)
High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study.
O. Solheim (1992)
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
G. Ceresoli (2008)
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
J. van Haarst (2002)
Thalidomide in patients with malignant pleural mesothelioma.
P. Baas (2005)
Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase.
P. Szlosarek (2013)
Antiproliferative effect of Aurora kinase targeting in mesothelioma.
S. Crispi (2010)
Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases
D. Lebwohl (2013)
The evolution of thalidomide and its IMiD derivatives as anticancer agents
J. Bartlett (2004)
Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma
D. Fennell (2012)
Everolimus for advanced pancreatic neuroendocrine tumors.
J. Yao (2011)
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).
M. Duvic (2007)
Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF‐C autocrine loops
R. Masood (2003)
A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group Study
B. Zidar (2004)
Advances in the systemic therapy of malignant pleural mesothelioma
D. Fennell (2008)
Phase II trial of high-dose cisplatin in patients with malignant mesothelioma.
D. Mintzer (1985)
MLN8054, an Inhibitor of Aurora A Kinase, Induces Senescence in Human Tumor Cells Both In vitro and In vivo
J. Huck (2010)
A new approach to the study of the base-excision repair pathway using methoxyamine.
M. Liuzzi (1985)
Multiarm, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling.
P. López (2014)
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).
M. O'Brien (2013)
Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)
F. Curnis (2000)
Carboplatin in malignant mesothelioma: A phase II study of the cancer and leukemia Group B
N. Vogelzang (2004)
Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours.
V. Gregorc (2010)
Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma
L. Strizzi (2001)
Aurora A selective inhibitor MLN8237 suppresses the growth and survival of HTLV‐1‐infected T‐cells in vitro
Mariko Tomita (2010)
Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
J. Weiss (2010)
SWOG S0722: Phase II Study of mTOR Inhibitor Everolimus (RAD001) in Advanced Malignant Pleural Mesothelioma (MPM)
S. Ou (2015)
The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine.
S. Kao (2012)
Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells
F. Wang (2015)
Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia
L. Garderet (2012)
Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer
B. Delage (2010)
Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies.
P. Ascierto (2005)
Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network.
Q. Li (2011)
Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.
J. Van Meerbeeck (1996)
Targeting epigenetic readers in cancer.
M. Dawson (2012)
Valproate, in Combination with Pemetrexed and Cisplatin, Provides Additional Efficacy to the Treatment of Malignant Mesothelioma
F. Vandermeers (2009)
Angiogenic cytokines in mesothelioma: a study of VEGF, FGF‐1 and ‐2, and TGF β expression
S. Kumar-Singh (1999)
A phase II study of gemcitabine in patients with malignant pleural mesothelioma
J. van Meerbeeck (1999)
Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
P. Zucali (2014)
Drug-sensitive FGFR2 mutations in endometrial carcinoma
A. Dutt (2008)
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
L. Rosiñol (2012)
Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma.
Evan S Glazer (2010)
Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer
X. Zhang (2008)
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
M. Reck (2014)
Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.
R. Liao (2013)
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
Matthew J Bott (2011)
Angiogenesis is an independent prognostic factor in malignant mesothelioma
J. Edwards (2001)
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.
N. Turner (2010)
Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis.
S. Popat (2015)
Antitumor Activity of BIBF 1120, a Triple Angiokinase Inhibitor, and Use of VEGFR2+pTyr+ Peripheral Blood Leukocytes as a Pharmacodynamic Biomarker In Vivo
K. Kudo (2010)
Reversible histone acetylation involved in transcriptional regulation of WT1 gene.
Yangguang Shao (2007)
Tumor Vascular Targeting with Tumor Necrosis Factor α and Chemotherapeutic Drugs
A. Corti (2004)
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
J. Baselga (2012)
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.
N. Campbell (2012)
Spreading of mesothelioma cells is rapamycin‐sensitive and requires continuing translation
E. Ranzato (2009)
1220TiPMULTI-ARM, NONRANDOMIZED, OPEN-LABEL PHASE IB STUDY TO EVALUATE FP1039/GSK3052230 WITH CHEMOTHERAPY IN NSCLC AND MPM WITH DEREGULATED FGF PATHWAY SIGNALING.
P. Garrido (2014)
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
P. Sonneveld (2012)
The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials
A. Synakiewicz (2014)
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
L. Garland (2007)
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
W. Buikhuisen (2013)
A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307
S. Dubey (2010)
EVALUATION OF TUMOUR ANGIOGENESIS AS A PROGNOSTIC MARKER IN MALIGNANT MESOTHELIOMA
S. Kumar-Singh (1997)
Structure-Activity Relationships of Linear and Cyclic Peptides Containing the NGR Tumor-homing Motif*
G. Colombo (2002)
MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors
T. Sells (2015)
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
R. Orlowski (2007)
Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.
H. Kindler (2005)
Phase II trial of five day intravenous infusion vinblastine sulfate in patients with diffuse malignant mesothelioma: A Southwest Oncology Group study
J. D. Cowan (2004)
Cell-cycle checkpoints and cancer
M. Kastan (2004)
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
F. Hilberg (2008)
A Randomized Phase II Study Adding Axitinib to Pemetrexed‐Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single‐Center Trial Combining Clinical and Translational Outcomes
W. Buikhuisen (2016)
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
G. Roth (2009)
The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions
P. Illei (2003)
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
D. Franz (2013)
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.
G. Ceresoli (2011)
An endotoxin-induced serum factor that causes necrosis of tumors.
E. Carswell (1975)
A phase I pharmacokinetic study of recombinant human tumor necrosis factor administered by a 5-day continuous infusion
A. Mittelman (2004)
Cisplatin and Gemcitabine in Malignant Pleural Mesothelioma: A Phase II Study
B. Castagneto (2005)
Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B
R. Govindan (2005)
This paper is referenced by
Combined use of irinotecan and p53 activator enhances growth inhibition of mesothelioma cells
Bo Han (2020)